8.10 USD
↘ 0.22 (2.65%)AT CLOSE (AS OF 07:31 PM EDT)
KMDA is currently priced at $8.10. The technical outlook is "Neutral" and the fundamental picture shows "Buy". This is driven by a robust Altman Z-Score, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, KMDA trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Sep 15, 2026.
Open?$8.17
High?$8.19
Low?$8.00
Prev. Close?$8.31
Volume?119.8K
Avg. Volume?166.8K
VWAP?$8.09
Rel. Volume?0.72x
Bid / Ask
Bid?$6.79 × 100
Ask?$9.89 × 100
Spread?$3.10
Midpoint?$8.34
Valuation & Ratios
Market Cap?479.6M
Shares Out?N/A
Float?31.4M
Float %?54.6%
P/E Ratio?N/A
P/B Ratio?6.91
EPS?-$0.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?100
Momentum?65
Short Sent.?70
Piotroski F-Score?5/9Mixed
Altman Z-Score?6.87Safe
Confidence?66%Moderate
Short InterestLow
Short % of Float?0.50%Low
Short Interest?156.8K
Days to Cover?1.0
Free Float31.4M
Avg Daily Volume181.9K
Settlement Date2026-08-31
Financial Health
Current Ratio?3.55Strong
Quick Ratio?2.24Strong
Cash Ratio?0.33Low
Debt/Equity?0.03Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?6.91FAIR▾
Peers100
S&P27
P/S?6.34FAIR▾
Peers100
S&P20
P/FCF?N/A▾
EV/EBITDA?-147.7CHEAP▾
S&P97
EV/Sales?6.28HIGH▾
Peers100
S&P26
Returns & Efficiency
ROE?-10.8%WEAK▾
S&P9
ROA?-7.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-8119000
Enterprise Value?$474.4M
Fundamentals ratios updated end of day